The oncoprotein NPM-ALK of anaplastic large cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling

Authors:
Staber PB, Vesely P, Haq N, Ott RG, Funato K, Bambach I, Fuchs C, Schauer S, Linkesch W, Hrzenjak A, Dirks WG, Sexl V, Bergler H, Kadin ME, Sternberg DW, Kenner L, Hoefler G
In:
Source: Blood
Publication Date: (2007)
Issue: 110(9): 3374-83
Research Area:
Immunotherapy / Hematology
Cells used in publication:
Karpas 299
Species: human
Tissue Origin: blood
Platform:
Nucleofectorâ„¢ I/II/2b
Abstract
Anaplastic large cell lymphomas (ALCL) are highly proliferating tumors that commonly express the AP-1 transcription factor JunB. ALK fusions occur in about 50% of ALCL, and among these 80% have the t(2;5) translocation with NPM-ALK expression. We report greater activity of JunB in NPM-ALK positive than in NPM-ALK negative ALCL. Specific knockdown of JUNB mRNA using small interfering RNA and small hairpin RNA in NPM-ALK expressing cells decreases cellular proliferation as evidenced by a reduced cell count in the G2/M phase of the cell cycle. Expression of NPM-ALK results in ERK1/2 activation and transcriptional upregulation of JUNB. Both NPM-ALK positive and negative ALCL tumors demonstrate active ERK1/2 signaling. In contrast to NPM-ALK negative ALCL, the mTOR pathway is active in NPM-ALK positive lymphomas. Pharmacological inhibition of mTOR in NPM-ALK positive cells downregulates JunB protein levels by shifting JUNB mRNA translation from large polysomes to monosomes and ribonucleic particles (RNPs), and decreases cellular proliferation. Thus, JunB is a critical target of mTOR and is translationally regulated in NPM-ALK positive lymphomas. This is the first study demonstrating translational control of AP-1 transcription factors in human neoplasia. In conjunction with NPM-ALK, JunB enhances cell cycle progression and may therefore represent a therapeutic target.